



ONCO-INNOVATIONS

Transforming Oncology Through Science and AI Technology

CBOE: **ONCO** | FSE: **W1H** | OTCQB: **ONNVF**

2025



Forward Looking Statements and Disclaimer



FORWARD LOOKING STATEMENTS

This presentation contains “forward looking information” within the meaning of applicable Canadian securities legislation. Wherever possible, words such as “plans”, “expects”, or “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, have been used to identify forward looking information. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Onco-Innovations Limited (the “Company”) to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Management believes that the assumptions and expectations reflected in such forward looking statements are reasonable.

MARKET DATA DISCLAIMER

This presentation includes market and industry data that has been obtained from third party sources including publications from various industries, and where appropriate, certain numbers, including dollar amounts, have been rounded out by us to avoid lengthy numbers. We believe that this industry data is accurate and that its estimates and assumptions are reasonable; however, there are no assurances as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable; however there are no assurances as to the accuracy or completeness of included information. Although the data is believed to be reliable, we have not independently verified any of the data from third party sources referred to in this presentation or ascertained the underlying economic assumptions relied upon by such sources. nager of a syndicate. If a firm is less established, the firm, and not the investment bank, tends to make the pitch to secure the relationship.



Executive Summary




Onco Innovations is a dual-platform oncology company that unites breakthrough **DNA repair-targeted therapeutics** with **AI-driven precision oncology** to redefine how cancer is treated.



Mission-Driven Innovation

Committed to revolutionizing oncology care by delivering life-saving treatments through precision medicine and cutting-edge AI technologies.



Therapeutics Platform

Advancing first in class PNKP inhibitors targeting a novel DNA repair enzyme. Colorectal cancer focus and beyond, with nanoparticle delivery for targeted action and minimal toxicity.



AI and Data Platform

Synograph - a proprietary causal AI engine, helps predict treatment outcomes and optimizes clinical trial design. Real world data integration facilitates patient stratification and regulatory-grade insights.



Market Opportunity and Scalability

Positioned in a \$500 billion global oncology market, with the precision medicine market projected to grow from \$87.5 billion in 2023 to \$249.24 billion by 2030, achieving a total growth of 184.8%.

\$500B Oncology Market Reference: <https://www.biospace.com/laxman-dige-precendenceresearch-com>



Global Cancer Market Size


An Immense Investment Opportunity in Oncology



131%

Aggregate Growth Expected by 2032

10 Year Growth Projection Market Value in Billions \$(USD)



- ✓ Global cancer cases are projected to rise by **47% by 2040**¹
- ✓ CAGR of **8.9%**²
- ✓ Existing treatment gaps in precision medicine and early diagnostics
- ✓ **Addressable market:** Colorectal cancer alone represents a **\$18 billion market**
- ✓ Unmet needs include **safer and more cost-effective therapies**

Source 1: <https://pubmed.ncbi.nlm.nih.gov/33538338/#:~:text=The%20global%20cancer%20burden%20is,critical%20for%20global%20cancer%20control>

Source 2: <https://www.novaoneadvisor.com/report/oncology-market>

Source 3: <https://www.novaoneadvisor.com/report/sample/7686>

Source 4: <https://www.precedenceresearch.com/colorectal-cancer-therapeutics-market>



Colorectal Cancer: A Critical Focus

Addressing the **Second Leading Cause** of Cancer Deaths



Affects 1.9M people annually¹

Causes 900,000 deaths worldwide¹



4th Most Common Cancer²

Sporadic cases (no family history) account for 70%³

Targeted Treatment Matters

- **90% survival** rate for early-stage diagnosis vs. **14%** for late-stage
- **40%** of sporadic CRC patients die due to distant metastases
- More than 9 out of 10 diagnosed with **early stage** CRC that has not spread beyond the colon or rectum survive 5 years, **and many much longer**

<https://www.gene.com/stories/understanding-colorectal-cancer>

Challenges

- ✗ Limited access to precision based treatments⁴
- ✗ Ineffective treatments for advanced cases⁵

Onco's Solutions

- ✓ **AI Patient Identification:**
Uses AI for precision medicine via Inka
- ✓ **Patient-Centered Care:**
Bridging treatment gaps for better outcomes

Source 1: <https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660>
Source 2: <https://www.wcrf.org/wp-content/uploads/2024/10/Colorectal-cancer-report.pdf>
Source 3: [https://www.ncbi.nlm.nih.gov/books/NBK470380/#:~:text=Most%20colon%20cancer%20is%20sporadic%20\(70%25\),but%20n%20identifiable%20inherited%20mutation](https://www.ncbi.nlm.nih.gov/books/NBK470380/#:~:text=Most%20colon%20cancer%20is%20sporadic%20(70%25),but%20n%20identifiable%20inherited%20mutation)
Source 4: <https://pmc.ncbi.nlm.nih.gov/articles/PMC8785861/>
Source 5: https://www.upi.com/Health_News/2024/05/17/cancer-treatments-us-less/7421715951465/



Our PNKP Technology

100% Licensed PNKP Technology Driving Oncology Innovation

Our technology focuses on
Polynucleotide Kinase 3'-Phosphatase
(PNKP) inhibitors.

Highlights



Pre-clinical studies
have shown
effectiveness in
relation to **multiple
cancers**



Synergizes with
tumor-suppressing
genes (SHP-11, PTEN2)



5 Patents protecting
PKNP technology and
ONCO10™

ONCO10™ is a proprietary term of Onco-Innovations. Trademark registration is pending.

Key Innovation

- ✓ Targets Polynucleotide Kinase 3'-Phosphatase (PNKP) to block DNA repair in cancer cells
- ✓ Proprietary Polynucleotide Kinase 3'-Phosphatase (PKNP) inhibitor powers **ONCO10™**, our drug candidate

Future Expansion

Foundation for oncology advancements beyond
colorectal cancer, such as GBM (Glioblastoma
multiforme) and ovarian cancer etc.





Our **Proprietary Lead Drug Candidate**
Utilizing PNKP Technology (A83B4C63)



Cancer-Targeted Approach

- ✓ **Proprietary Formula:** Aims to prevent DNA repair to eliminate cancer cells
- ✓ **Enhanced Delivery:** Nanoparticle encapsulation assists precision targeting
- ✓ **Optimized Results:** Designed to work with chemo/radiation/surgery to potentially improve outcomes and **reduce side effects**



Key Advantages

- ✓ **Scalable across multiple cancer types**
- ✓ Supported by **5 patents** safeguarding innovation and market leadership



ONCO10™ is a proprietary term of Onco-Innovations. Trademark registration is pending.



Preclinical Validation - Colorectal Drug Success



Preclinical Validation: Tumor Reduction and Survival Impact Existing Results in Animal Models




- ✓ Mouse studies reveal **A83B4C63**, a novel nanoparticle formulation, demonstrates increased survival and slower growth of PTEN -/- tumors
- ✓ Compared to placebo, A83B4C63 showcased solid performance, **reducing tumor growth**
- ✓ **Low toxicity** profiles further validate its potential for further study
- ✓ Nanoparticle formulation A83B4C63 in combination with radiation slowed the growth of tumors in colorectal-cancer bearing mice, performing better than radiation treatment alone

Sadat et al. A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3'-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer. J Control Release. 2021 Jun 10;334:335-352. doi:10.1016/j.jconrel.2021.04.034.



Path to Regulatory Approval

A Regulatory Roadmap for PKNP Drug Candidates



Validated Preclinical Data

Preclinical studies confirm both safety and efficacy, establishing a strong foundation for regulatory submissions and clinical trials.

1.



Regulatory Milestones

FDA submission targeted for 2026, with Phase I trials anticipated to begin mid-2026, focusing on safety and dosage.

2.



Potential for Fast-Track Eligibility

Oncology therapies addressing high unmet needs increase the likelihood of expedited regulatory reviews, such as Fast-Track Designation.

3.



Global Multi-Region Strategy

Plans include submissions to the FDA, EMA, and Asia-Pacific regulatory agencies to maximize international market reach.

4.



World-Class Leadership Team



Executive Team and Board of Directors



Thomas O'Shaughnessy
CEO

Healthcare Strategy Expert | 25 Years Experience.

Former Partner, Deloitte Canada – Led health & digital initiatives.

Managing Principal Carnarvon Strategies – Healthcare & life sciences strategy.

MSc, Oxford University.




Dr. Richard Heinzl
Director

Founder, Doctors Without Borders Canada – Nobel Peace Prize (1999).

CEO, My Next Health Inc. – Leading functional genomics innovation.

Former Global Medical Director, WorldCare (Harvard-affiliated).

Degrees from McMaster, Harvard, and Oxford – Global healthcare & genomics expert.



Nico Mah
CFO & Corp Secretary

Chartered Professional Accountant (CPA) with nearly 8 years of experience.

Former Manager, PwC – Specializing in audit, tax, and consulting.

Expert in financial reporting & corporate accounting.



Zachary Stadnyk
Director

Experienced Public Company Executive with 15+ years leading multi-million-dollar initiatives across Healthcare, Technology, Wellness, Cannabis, and Private Equity.

Former Head of Life Sciences & Innovation, TMX Group – Led growth strategies for emerging biotech and innovation companies.



Christopher Gulka
Director

CFA & CPA with 30+ years of experience.

Founder, Working Capital Corporation – specializing in valuations & corporate finance.

Former CFO & Director, Inner Spirit Holdings Ltd. – financial leadership across multiple sectors.

BCom (Distinction), University of Alberta.



Maximilian Justus
Director

Public Company Executive with expertise in fashion & apparel.

CEO & Director, Grounded People Apparel (Since 2020) – Leading strategy & market expansion.

Experienced in operations & growth initiatives.



Scientific and Clinical Advisory Board

Our Scientific and Clinical Advisory Board provides unparalleled expertise in oncology and drug development



Dr. Dennis Hall

Dr. Hall, Professor of Chemistry and Canada Research Chair in Organoboron Chemistry for Catalysis and Drug Discovery at the University of Alberta, specializes in the development of innovative chemistry and its translation to the treatment of cancer (DNA repair) and infectious diseases. An elected Fellow of the Royal Society of Canada, his research in organic synthesis was recognized by international lectures and awards.



Dr. Afsaneh Lavasanifar

Dr. Lavasanifar, Professor in Pharmaceuticals at the University of Alberta, is a global leader in polymerbased drug delivery systems, focusing on nano-carriers for cancer immunotherapy and anti-inflammatory treatments. With over 170 publications, 10 patents, and prestigious awards, she also serves as Scientific Chief Officer at Meros Polymers Inc., advancing innovative therapeutics from her lab's technology.



Dr. Michael Lock

Dr. Michael Lock is a professor at the University of Western Ontario with training in radiation oncology from top institutions. He has led major programs including Radiation Oncology Chair, Medical Director of the London Regional Cancer Program, and provincial advisory roles. A recognized leader in multidisciplinary cancer care, he collaborates globally with the IAEA, UN, and WHO. He also holds management training from Rotman and has received awards like the Human Touch and MAC Administrative Awards.



Dr. John Mackey

Dr. Mackey, Professor Emeritus in Oncology at the University of Alberta, is a leader in cancer clinical trials, drug development, and novel diagnostics. He co-founded Pacylex Pharmaceuticals, advancing first-in-class anticancer therapies, and leads illumiSonics, pioneering real-time molecular histology. With over 300 publications, 12 patents, and innovations in clinical trial analytics, he was inducted as a Fellow of the Canadian Academy of Health Sciences.



Scientific and Clinical Advisory Board

Our Scientific and Clinical Advisory Board provides unparalleled expertise in oncology and drug development



Dr. Islam Mohamed (Chair)

Dr. Mohamed, a Radiation Oncologist at BC Cancer, specializes in lung, breast, skin cancers, and sarcoma, with expertise in stereotactic radiation. A clinical investigator and research ethics board member, he contributes to cancer genomics, radiobiology, and oncology research. He also advises and invests in Canadian biotech companies, including Linax Technologies, IllumiSonics, and ASEP Medical.



Dr. Michael Weinfeld

Dr. Weinfeld, Professor of Oncology at the University of Alberta and Senior Scientist at Alberta Health Services, brings over 40 years of expertise in cancer research. Based at the Cross Cancer Institute, his groundbreaking work focuses on DNA damage and repair, advancing therapies to make cancer cells more vulnerable to radiotherapy and chemotherapy.



Dr. Frederick West

Dr. West, Allard Research Chair in Oncology at the University of Alberta, specializes in chemical synthesis and structural modification of organic molecules. A key contributor to developing DNA repair inhibitors, his innovative work enhances the efficacy of chemotherapy and radiotherapy in cancer treatment.



Inka Health: Transforming Oncology Through SynoGraph™ AI



Inka Health



ONCO-INNOVATIONS

Transformative Acquisition to Lead the Future of Oncology

Acquisition Details

- **100% Acquisition of Inka Health AI** for \$3M (CAD) in Onco common shares
- Closed: **February 4th, 2025**

SynoGraph™ AI Integration

- **Novel AI:** Accelerates identification of patient cohorts most likely to benefit from specific therapies leading to personalized treatments
- Aims to enhance drug development timelines and boosts pipeline efficiency, complimenting Onco's technology and pipeline

Strategic Big Pharma Partnerships

- Trusted by **top pharmaceutical leaders**
- Scaling global impact through established collaborations


A World-Class Nobel Prize Winning Oncology Team

- **Global Experts** in AI, oncology, and precision medicine
- Proven success in partnerships **with leading pharma companies**



Scientific Leadership Team

Sit as members of Onco-Innovations' Scientific and Clinical Advisory Board



Dr. Paul Arora


Co-Founder of Inka Health

- Epidemiologist
- Successfully exited founder of Lighthouse Outcomes
- 50+ scientific publications
- A decade of senior leadership positions in global consulting



Dr. Steven Jones

- Genomicist
- Director, Genome Sciences Centre at BC Cancer
- 500+ Scientific publications in Genomics and Cancer
- Founder of Ifowonco Bioinformatics Inc and Alamy Health, PBC
- Canada Research Chair in Computational Genomics



Dr. Winson Cheung

- Medical Oncologist (GI)
- Head of Oncology Outcomes Research Group
- Former CDA Expert Review Committee member & Flatiron Health Advisor
- 300+ scientific publications
- \$20MM+ in scientific funding




Dr. James Orbinski

- Scientific Advisor
- **Nobel Peace Prize Recipient on behalf of MSF**
- Globally renowned humanitarian, scholar, and Officer of the Order of Canada
- Founding Director of York University's Dahdaleh Institute for Global Health Research
- Former International Council President (Doctors Without Borders)



Scientific Leadership Team

Continued



Dr. Alind Gupta

Co-Founder of Inka Health

- Adjunct Professor at the University of Toronto
- Expert in real-world evidence, AI, and causal inference methods
- Led advanced analytics projects at a major U.S. consultancy
- Globally referenced author in health technology assessment (HTA) guidance documents



Dr. Edward Mills

- Co-founder of MTEK Sciences and Redwood Outcomes, both acquired by major industry players
- Principal investigator of multiple adaptive platform trials and large-scale studies
- Author of over 550 peer-reviewed papers in top journals such as NEJM, The Lancet, and JAMA



Dr. Kristian Thorlund


- Co-founder of Redwood Outcomes, MTEK Sciences (both acquired), and rAire
- Founder of Biospark.ai
- Leading biostatistician specializing in Bayesian methods
- Named a Clarivate Analytics Highly Cited Researcher for significant impact in the field



Inka's Proprietary & Patented AI SynoGraph™



SynoGraph™ is Inka's flagship asset, a revolutionary AI-enabled platform that aims to enhance the precision and efficiency of oncology treatment planning.




Impact: Aims to enable oncologists to better identify patients who will benefit from precision medicines.
Aims to enhance drug development timelines and boosts pipeline efficiency.






SynoGraph™ Turning Complexity into Clarity



SynoGraph
Network-based causal AI



MacBook Pro



■ Our Big Pharma Clients

■ Our Data Partners



CANADA'S MICHAEL SMITH
GENOME
SCIENCES
CENTRE



Big Pharma Clients and World-Class, Exclusive Data Partners

AstraZeneca Canada became a client of Inka Health on September 23, 2024, prior to Inka Health becoming part of Onco Innovations on February 3 2025. To the Company's knowledge, AstraZeneca is not an investor in Onco Innovations. References to collaboration between Inka and AstraZeneca Canada are to the real-world evidence and analytic methods work being developed under the services agreement between them.



ONCO + INKA

Uniting cutting-edge AI with novel therapies to accelerate cancer drug development and treatment



ONCO-INNOVATIONS

Completely new class of therapy: Novel mechanism of action (patented PNKP inhibitors) and ONCO10™ drug formulation augments existing therapies (chemo and radition).

Targeted Delivery & Targeted Treatment: Novel nanoparticle encapsulation aims to enhance precision targeting.

Optimized Results: Results of animal trials demonstrated reduction in colorectal cancer tumour size and growth, particularly when combined with ionizing radiation, expandable to other cancer indications.



Inka Health

Novel AI: AI platform and access to precision medicine data sets aims to enable faster and more precise stratification of tumours and how they will respond to ONCO10™.

Expansion of indications: AI platform accelerates R&D capabilities to expand application of PNKP and ONCO10™ beyond indications beyond colorectal cancer.

With the application of real-world evidence, Onco + Inka are focused on facilitating the next level of AI patient identification and therapeutic intervention in a \$400+ global oncology treatment market.¹

Source 1: <https://www.precedenceresearch.com/colorectal-cancer-therapeutics-market>



ONCO Public Company Comparables



A Unique AI-Driven Biotech Advancing the Future of Cancer Therapeutics

Data as of Sep 22th, 2025

Source 1: <https://kuraoncology.com/clinical-trials/#ziftomenib>
 Source 2: <https://www.verastem.com/research/pipeline/>
 Source 3: <https://www.bicara.com/science/>
 Source 4: Google Finance

Company	Product Pipeline	AI of Biotech	Phase	Market Cap (in USD) ⁴
 KURA ONCOLOGY	Ziftomenib – Acute myeloid leukemia (AML) (Blood cancer treatment)	Biotech	Phase 1 ¹	(KURA) \$702M
 VERASTEM ONCOLOGY	Avutometinib (VS-6766) – Targets Ovarian cancer	Biotech	Phase 2 ²	(VSTM) \$561M
 BICARA THERAPEUTICS™	Ficerafusp alfa – Cancer in the head & neck and various types of solid cancers	Biotech	Phase 1 ³	(BCAX) \$586M
 HEALWELL AI	HEALWELL AI System – Early detection of cancers and rare diseases	AI	NA	(AIDX) \$300M
 compugen FROM CODE TO CURE®	COM503-701-902 – Targets Cancer Solid tumors Rilvegostomig – Solid tumors (PD-1/TIGIT bispecific antibody) Unigen™ AI Platform – Cancer (AI-driven predictive platform for discovering drug targets))	AI & Biotech	NA	(CGEN) \$138M
 ceribell® Clarity When It's Critical	Ceribell System – Neurology (AI-powered EEG for rapid seizure detection and monitoring in critical care)	AI	NA	(CBLL) \$446M
 ONCO-INNOVATIONS	Novel DNA Damage Repair Target PNKP and Real World Evidence Analytics powered by AI	AI & Biotech	Phase 1	(ONCO) \$76M




Onco-Innovations Milestones



Achieved

Anticipated



Research & Development Overview

Four progressive streams with leading research and development partners



R&D Stream	Description/Purpose	Recent Developments
Discovery	▪ Extend proprietary knowledge of A83 (e.g. in silico modeling of PNKP inhibition) ▪ Anticipate future clinical indications (Glioma, Human Ovarian Cancer)	▪ June 2025: Partner with University of Alberta to research PNKP Inhibition in Hard-to-Treat Cancers ▪ July 2025: Engage Redwood AI's computational chemistry platform to model A83-protein interactions and optimize activity
Manufacturing	▪ Progress from GLP to GMP for API and Excipient Manufacture ▪ Supply material for in vitro testing ▪ Scale manufacture for extended animal and clinical testing	▪ May 2025: Partner with Dalton Pharma to start manufacturing of preclinical testing material for PNKP Inhibitor Technology ▪ September 2025: Dalton commences activities to manufacture the nanoparticle formulation (PEO-b-PBz-CL)
Preclinical Testing	▪ GLP pre-clinical testing program ▪ Genotoxicity, ADME evaluation ▪ Preclinical toxicology (rodent/non rodent) ▪ Separate testing of API, Excipient, and Encapsulated API	▪ July 2025: Agreement with Nucro-Technics to conduct IND-enabling preclinical studies for PNKP inhibitor ▪ September 2025: Nucro-Technics begins analytical development for PNKP Technology
Clinical Translation	▪ Clinical Development Program: To initiate IND and regulatory submissions for Phase 1 clinical trial ▪ First in Human Study: Monotherapy in PTEN and SHP-1 Deficient Malignancies	▪ August 2025: Avance Clinical Start-Up Agreement to advance preparations for first-in-human trial of PNKP inhibitor. Currently evolving trial program



Highlights of Onco-Innovations

A cutting edge dual platform oncology company that unites breakthrough DNA repair-targeted therapeutics with AI-driven precision oncology to redefine how cancer is treated—and who benefits.



✓ Proprietary Drug Candidate Portfolio

- Novel colorectal cancer therapy candidates addressing an initial and growing \$12 billion market¹
- Patented PKNP technology and ONCO10™ for targeted drug development and defined clinical pathways and partners

✓ World-Class Leadership Team

- Decades of experience in biotechnology, AI, and clinical innovation
- Success in public offerings, global partnerships, and award-winning research

✓ AI and Data Platform

- Industry-leading AI solutions enhancing cancer drug development and treatment
- Real world data integration facilitates patient stratification and regulatory-grade insights.

✓ Market Opportunities

- The global oncology market exceeds \$200 billion², with precision medicine projected to grow by 184.8% by 2030³
- Oncology⁴, diagnostics⁵, and precision medicine⁶ combined exceed \$750B by 2030

✓ Strong Competitive Advantage

- First-mover advantage combining proprietary drug therapies with advanced AI technology
- Synergies between Onco and Inka create scalability and innovation

Source 1: <https://www.precedenceresearch.com/colorectal-cancer-therapeutics-market>
Source 2: <https://www.biospace.com/laxman-dige-precedenceresearch-com>
Source 3: <https://www.grandviewresearch.com/press-release/global-precision-medicine-diagnostics-therapeutics-market#:~:text=Precision%20Medicine%20Market%20Growth%20&%20Trends,of%20different%20types%20of%20cancers>
Source 4: <https://www.novaoneadvisor.com/report/sample/7686>

Source 5: <https://www.towardshealthcare.com/insights/cancer-diagnostics-market-sizing>
Source 6: <https://www.grandviewresearch.com/press-release/global-precision-medicine-diagnostics-therapeutics-market#:~:text=Precision%20Medicine%20Market%20Growth%20&%20Trends,of%20different%20types%20of%20canc>



Capital Structure

As of Sep 19th, 2025



ONCO-INNOVATIONS

CBOE: ONCO | FSE: W1H | OTCQB: ONNVF



Common Shares Issued & Outstanding		54,283,052
Warrants		1,258,586
Granted on:	Amount	Exercise Price
March 28, 2024	175,000	\$0.10*
November 26, 2024	235,600	\$0.60**
February 3, 2025	204,083	\$2.55
April 30, 2025	400,000	\$1.60
August 13, 2025	243,903	\$2.05
Stock Options		654,785
Granted on:	Amount	Exercise Price
January 9, 2025	535,000	\$1.20
July 15, 2025	119,785	\$1.86
RSU's		2,490,000
Issued & Outstanding Fully Diluted		58,686,423

*\$0.10 distribution round warrants held across 70 investors with a maximum allocation of 2,500 warrants per investor.

** Over 90% of \$0.60 warrants have been exercised.





ONCO-INNOVATIONS

CBOE: ONCO | FSE: W1H | OTCQB: ONNVF

Onco-Innovations Limited.



1309 – 7th Street SW
Calgary, Alberta, Canada
T2R 1A5

Thank You



1 (888) 261 – 8055



www.oncoinnovations.com



investors@oncoinnovations.com

CBOE: ONCO | FSE: W1H | OTCQB: ONNVF